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ABSTRACT   24 
G-quadruplexes are DNA or RNA secondary structures that can be formed from 25 
guanine-rich nucleic acids.  These four-stranded structures, composed of stacked 26 
quartets of guanine bases, can be highly stable and have been demonstrated to 27 
occur in vivo in the DNA of human cells and other systems, where they play 28 
important biological roles, influencing processes such as telomere maintenance, 29 
DNA replication and transcription, or in the case of RNA G-quadruplexes, RNA 30 
translation and processing.  We report for the first time that DNA G-quadruplexes 31 
can be detected in the nuclei of the malaria parasite Plasmodium falciparum, which 32 
has one of the most A/T-biased genomes sequenced and therefore possesses few 33 
guanine-rich sequences with the potential to form G-quadruplexes.  We show that 34 
despite this paucity of putative G-quadruplex-forming sequences, P. falciparum 35 
parasites are sensitive to several G-quadruplex-stabilizing drugs, including quarfloxin 36 
which previously reached Phase-2 clinical trials as an anticancer drug.  Quarfloxin 37 
has a rapid initial rate of kill and is active against ring stages as well as replicative 38 
stages of intraerythrocytic development.  We show that several G-quadruplex-39 
stabilising drugs including quarfloxin can suppress the transcription of a G-40 
quadruplex-containing reporter gene in P. falciparum, but that quarfloxin does not 41 
appear to disrupt the transcription of rRNAs, which was proposed as its mode of 42 
action in both human cells and trypanosomes.  These data suggest that quarfloxin 43 
has potential for repositioning as an antimalarial with a novel mode of action.  44 
Furthermore, G-quadruplex biology in P. falciparum may present a target for 45 
development of other new antimalarial drugs. 46 
 47 
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IMPORTANCE  48 
The malaria parasite Plasmodium falciparum has historically become resistant to 49 
every antimalarial drug deployed, leading to a constant demand for new drugs and 50 
novel molecular targets for their development.  G-quadruplex DNA motifs have been 51 
studied as a possible target for anti-cancer drugs, yielding an abundance of G-52 
quadruplex-binding compounds, several of which have undergone clinical trials 53 
although none has yet reached the clinic.  Here, we examine the existence and 54 
function of G-quadruplex motifs in the P. falciparum genome, and investigate the 55 
possibility of repurposing G-quadruplex-binding compounds as novel antiplasmodial 56 
agents.  We show that G-quadruplex DNA motifs can be detected in the P. 57 
falciparum genome, and can modulate expression of a G-quadruplex-containing 58 
reporter gene.  We also show that one G-quadruplex-binding drug, which previously 59 
underwent Phase-2 clinical trials, is potent and fast-acting against the 60 
intraerythrocytic stages of the parasite in vitro.  G-quadruplexes thus constitute a 61 
possible new drug target in P. falciparum.  62 
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INTRODUCTION 63 
Protozoan Plasmodium parasites are the causative agents of human malaria, a 64 
disease responsible for widespread morbidity and about half a million deaths each 65 
year (1).  Most malaria deaths are caused by the species P. falciparum, although five 66 
other Plasmodium species also infect humans. P. falciparum has one of the most 67 
A/T-biased genomes ever sequenced, at ~81% A/T (2).  Interestingly, not all 68 
Plasmodium species share this feature: the genome of the second major human 69 
malaria parasite, P. vivax, is only ~58% A/T, whereas the genome of the well-studied 70 
rodent malaria species, P. berghei, is more similar to P. falciparum at ~78% A/T (3, 71 
4).   72 
 The A/T-biased genome in species like P .falciparum results in an extreme 73 
paucity of guanine-rich sequences, and hence of putative G-quadruplex forming 74 
sequences, or ‘PQSs’ (5).  The G-quadruplex is one of many non-double-helical 75 
secondary structures that can be formed by DNA, alongside triplexes, hairpins, etc.  76 
To form an intramolecular G-quadruplex motif, four tracts of at least three guanines 77 
are required in close proximity, in order to form the type of structure shown in Figure 78 
1A (6).  Genome sequences can thus be mined for PQSs by searching for the 79 
consensus sequence G3 N1-7 G3 N1-7 G3 N1-7 G3 (7), although there is increasing 80 
evidence that G-quadruplexes may also fold with longer loops between the guanine 81 
tracts, with non-guanine ‘bulges’, and in ‘inter-molecular’ modes that involve both the 82 
sense and antisense strands of a DNA sequence (8, 9).  Nevertheless, when the P. 83 
falciparum genome was analysed for conventional intramolecular PQSs, only 80 84 
were found in genes or intergenic regions (5, 10).  This translates to only one PQS 85 
per ~300kb of the non-telomeric P. falciparum genome, compared to an average of 86 
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one PQS per kb in the human genome (7).  Several hundred PQSs were also found 87 
in the P. falciparum telomeres, which have the repeat sequence GGGTT(T/C)A and 88 
are inherently able to form G-quadruplexes (11, 12).  Predicting the ‘expected’ PQS 89 
density of a given genome is not straightforward due to variable genome composition 90 
and biased base dyad frequencies, but under the simplest predictive algorithm (a 91 
Bernoulli stream of random bases at 81% A/T), a genome with the size and 92 
composition of P. falciparum contains no PQSs at all (5), therefore the maintenance 93 
of PQSs in specific genomic regions is likely to be biologically functional. 94 
 G-quadruplexes can have many important biological roles, including 95 
regulating telomere structure (13), inhibiting gene transcription (14) and promoting 96 
recombination, probably via stalling of RNA polymerases and replicative 97 
polymerases respectively (15, 16).  In P. falciparum we have recently shown that 98 
PQSs are primarily clustered within the coding sequence or upstream of the major 99 
virulence gene family var, and that mitotic recombination events amongst var genes 100 
are strongly spatially associated with PQSs (5), so one role for G-quadruplexes in P. 101 
falciparum could be to promote the generation of var gene diversity.  Here, we set 102 
out to establish experimentally whether G-quadruplexes are more broadly important 103 
for the biology of P. falciparum.  If so, then interfering with G-quadruplex metabolism 104 
might be expected to affect the growth of the parasite and this would raise the 105 
possibility of repositioning G-quadruplex-binding compounds as antimalarial drugs.  106 
Many G-quadruplex-binding compounds have been developed in recent years, 107 
primarily as anticancer agents because several oncogenes such as c-myc are 108 
controlled by G-quadruplexes (14) and G-quadruplexes are also involved in telomere 109 
regulation (13).  Thus, drugs that interfere with these processes can affect the 110 
viability of cancer cells more severely than normal cells.  Similarly to rapidly-dividing 111 
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cancer cells, all single-celled eukaryotic pathogens must maintain their telomeres in 112 
order to survive as they replicate within their hosts, so telomere disruption would be 113 
one possible avenue for antimalarial activity of G-quadruplex-binding compounds.  In 114 
fact, some such compounds have already been shown to bind to the P. falciparum 115 
telomere repeat (11).  Alternatively, antimalarial activity might be achieved by 116 
disrupting the transcription or translation of essential G-quadruplex-containing 117 
genes, or by inducing a DNA damage response to G-quadruplex-stalled replication 118 
forks. 119 
In addition to the established potential of G-quadruplex-binding drugs as 120 
anticancer agents, a precedent for their potential as anti-parasitic agents was 121 
recently published.  Rudenko and co-workers, in the course of investigating RNA 122 
polymerase I inhibitors for their potency against Trypanosoma brucei, showed that 123 
the G-quadruplex-binding fluoroquinolone compound quarfloxin is trypanocidal with 124 
an IC50 of only 155nM (17).  Quarfloxin disrupts RNA polymerase I activity by binding 125 
to G-quadruplexes in repetitive rRNA genes in the nucleolus, disrupting their 126 
physiological interaction with nucleolin and ultimately preventing rRNA transcription 127 
(18, 19).  Cancer cells are hypersensitive to RNA polymerase I disruption (20) so 128 
quarfloxin was originally tested against neuroendocrine tumours and leukaemias but 129 
it was found to have poor bioavailability and to accumulate particularly in blood cells 130 
(21).  This latter property may have reduced its effectiveness against solid tumours 131 
but it raised the possibility of targeting intra-erythrocytic malaria parasites instead.  132 
We have tested this concept, showing that quarfloxin is indeed a potent and fast-133 
acting antiplasmodial compound in vitro, but that its mode of action is probably 134 
different from that demonstrated on human cells and trypanosomes. 135 
  136 
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RESULTS  137 
G-quadruplexes can be detected in P. falciparum nuclei  138 
The existence of G-quadruplexes in the P. falciparum genome has been predicted 139 
bioinformatically (5, 10) and PQSs from this genome have been shown to fold into G-140 
quadruplexes in vitro (10, 11).  To visualise G-quadruplex structures in cultured cells, 141 
structure-specific antibodies can be used, as demonstrated in mammalian cells (22-142 
24) and ciliate macronuclei (25).  Using immunofluorescence microscopy, we tested 143 
whether the G-quadruplex-specific antibody IH6 (24) could similarly recognise G-144 
quadruplexes in P. falciparum.  Clear nuclear staining was seen in all 145 
intraerythrocytic parasite stages (Fig .1B) and DNase treatment abolished this 146 
staining (but not the staining of a parasite protein, ERD2, used as a control).  RNase 147 
treatment, by contrast, had no observable effect (Fig. 1C).  A second independent G-148 
quadruplex-specific antibody, BG4 (23), also gave comparable nuclear staining (Fig 149 
S1).  G-quadruplex structures in DNA therefore appear to be consistently present 150 
during P. falciparum intra-erythrocytic development.             151 
G-quadruplex-stabilising drugs inhibit the growth of blood-stage malaria 152 
parasites  153 
If the G-quadruplexes detected in P. falciparum are important for parasite biology, G-154 
quadruplex stabilisation might be expected to affect the growth of the parasite.  We 155 
therefore tested the effect of several G-quadruplex-stabilising compounds on the in 156 
vitro growth of P. falciparum in a standard 48-hour assay encompassing one 157 
complete parasite growth cycle (26).   The antiplasmodial potency of the compounds 158 
N-methyl-mesoporphyrin IX (NMM) (27, 28), 5,10,15,20-tetra-(N-methyl-4-159 
pyridyl)porphine (TMPyP4) (29) and quarfloxin (18) varied widely, with EC50 values 160 
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ranging from 114nM for quarfloxin to 84M for NMM (Fig. 2A).  This variation could 161 
be due to the compounds having different G-quadruplex-stabilising capacities or 162 
varying affinities for different G-quadruplex isoforms, but it could also be due to off-163 
target effects (particularly given the high EC50 values determined for some of the 164 
compounds).  Therefore, to focus on G-quadruplex-binding properties alone, we 165 
directly compared the antimalarial potency of one of the compounds, TMPyP4, with a 166 
closely matched analogue, TMPyP2, which is structurally very similar but has a 167 
markedly lower G-quadruplex affinity via an alternative binding mode (30).  Parasite 168 
growth was affected ~ 18-fold more severely by TMPyP4 than by TMPyP2, 169 
suggesting that unimpeded G-quadruplex metabolism does have an important role in 170 
the healthy growth of parasites.  Furthermore, the most potent antiplasmodial activity 171 
in our panel of drugs was detected in quarfloxin, a drug that has already reached 172 
Phase-2 clinical trials. 173 
 Factors affecting the viability of a compound as a potential antimalarial drug 174 
include not only the EC50 but also the rate of kill.  Therefore, to further define the 175 
antiplasmodial activities of the G-quadruplex-stabilising compounds, their initial rates 176 
of kill were determined in trophozoite intraerythrocytic stages using the 177 
bioluminescence relative rate of kill (BRRoK) assay (31).  This assay uses a P. 178 
falciparum clone genetically engineered to express a luciferase reporter gene under 179 
a trophozoite-specific promoter.  Thus it can determine the concentration-dependent 180 
effect of a drug upon cell viability, by measuring the bioluminescence signal from the 181 
rapidly turned-over luciferase protein.  The loss of bioluminescence is benchmarked 182 
against the loss caused by a range of antimalarial compounds with well-defined rate 183 
of kill dynamics; shown here as dihydroartemisinin > chloroquine > mefloquine > 184 
atovaquone (Fig 2B). Comparison of the loss of bioluminescence signal after 6 hours 185 
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of exposure to the G-quadruplex-stabilising compounds indicated a range of initial 186 
RoK, with the rank order: NMM > quarfloxin > TMPyP2 = TMPyP4 (Fig 2C).  Relative 187 
to the antimalarial benchmarks, NMM exhibited a rapid cytocidal activity comparable 188 
to chloroquine; while quarfloxin was comparable to mefloquine at low concentrations 189 
and to chloroquine and dihydroartemesinin at high concentrations.  Neither TMPyP2 190 
nor TMPyP4 showed cytocidal activity during this 6-hour assay, potentially reflecting 191 
a lag-phase in their antiplasmodial activity (31).  These data were consistent with 192 
BRRoK data generated in a second strain of P. falciparum carrying the same 193 
luciferase reporter construct (Fig. S2A, B) and EC50 values were likewise consistent 194 
across two different strains (Fig. S2C).        195 
 196 
Quarfloxin targets all stages of the erythrocytic lifecycle, including the ring 197 
stage 198 
Whilst G-quadruplexes can be detected at all stages of the intraerythrocytic cycle 199 
(Fig. 1B), the BRRoK assay only effectively measures rate of kill in trophozoites 200 
because the luciferase reporter gene used in this assay is expressed from a 201 
trophozoite-specific promoter (31).  We therefore investigated the cytocidal effect of 202 
quarfloxin and NMM at other stages of the erythrocytic cycle by visual assessment of 203 
synchronised parasites together with flow-cytometric measurement of their DNA 204 
content.  Dead parasites do not synthesise new DNA, they tend to become visibly 205 
pyknotic and do not progress to the next morphological stage at the expected 206 
timepoint.  Figure 3 shows that quarfloxin was highly active against ring stages, 207 
preventing the great majority of them from ever progressing to trophozoites.  It was 208 
almost equally active against trophozoites, but less active against schizonts, a 209 
substantial proportion of which reinvaded to rings before dying in the next cycle.  By 210 
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contrast, although NMM appeared to be more potent than quarfloxin in the BRRoK 211 
assay, it showed little activity against rings, which were largely able to progress to 212 
trophozoites (Fig.S3).  Corroborating the BRRoK assay, however, NMM was potent 213 
against trophozoites and prevented them from progressing to schizonts.  These data 214 
point to different modes of antiplasmodial action for these two G-quadruplex-binding 215 
compounds. 216 
 217 
Quarfloxin does not affect telomere maintenance 218 
G-quadruplex-binding compounds may kill cells via a variety of molecular 219 
mechanisms, including inducing telomere dysfunction, disrupting DNA replication or 220 
disrupting the transcription of important genes (such as rRNAs, as discussed in the 221 
introduction).  The disruption of DNA replication seemed an unlikely mode of action 222 
for quarfloxin because it was highly potent against pre-replicative rings, but the 223 
disruption of gene transcription or an acute response to telomere dysfunction were 224 
both possibilities.  We therefore investigated these possible mechanisms, starting 225 
with the possibility of telomere dysfunction because the great majority of the PQSs in 226 
the P. falciparum genome are found in telomere repeats (10).  Parasites were grown 227 
in relatively low levels of quarfloxin (120nM, ~EC50) that could be tolerated for up to 228 
15 growth cycles, but no evidence of telomere shortening or lengthening was 229 
detected by telomere restriction-fragment Southern blotting after longterm exposure 230 
to quarfloxin (Fig. S4).   231 
The mode of action of quarfloxin may involve deregulated expression of PQS-232 
containing genes 233 
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To investigate the possibility that transcription of essential G-quadruplex-containing 234 
genes was deregulated by quarfloxin, we assessed the transcription of a validated 235 
G-quadruplex-containing reporter gene and also the transcription of rRNA genes.  236 
Firstly, reporter genes were designed and constructed using PQS-encoding genes 237 
that appear naturally in the P. falciparum genome.  The predominant gene group 238 
containing PQSs is the var virulence genes, but these are prohibitively large for 239 
cloning and many of the var-associated PQSs actually occur in the var upstream 240 
region rather than the coding sequence.  Therefore, two genes from a second family 241 
of variantly-expressed virulence genes were chosen: the rifin genes 242 
PF3D7_0700200 and PF3D7_1254400.  Only three out of ~200 rifin genes encode 243 
PQSs, compared to a larger proportion (30 out of 63) of the var genes (5) but 244 
crucially rifins have small sequences of ~1kb that are tractable for cloning.  The 245 
complete ORFs of these genes were therefore cloned into expression vectors with 246 
C-terminal tags which allowed their transcripts to be distinguished from those of the 247 
many other highly-homologous rifin genes in the family.  PF3D7_0700200 encodes a 248 
PQS in the sense orientation and PF3D7_1254400, in the antisense orientation.  The 249 
latter gene proved not to be expressed when transfected into parasites (a common 250 
issue with variantly-expressed gene families, data not shown) but the other gene, 251 
PF3D7_0700200, was successfully transcribed in transfected parasites.  252 
 To confirm that the PQS within this reporter gene could indeed form a G-253 
quadruplex structure, 1H NMR experiments were conducted with a synthetic 254 
oligonucleotide from this gene (Fig. 4A), revealing the presence of characteristic 255 
imino protons signals (chemical shift between 10 and 12 ppm) when the oligo was 256 
folded in the presence of potassium (Fig. 4B).  The oligo also showed a 295 nm 257 
thermal denaturation curve typical of G-quadruplexes, with a half denaturation (Tm) 258 
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at 49°C (Fig. 4C), indicating that the G-quadruplex formed by this sequence is likely 259 
to be stable at physiological temperature.   260 
 To confirm that this G-quadruplex structure could be targeted by G-261 
quadruplex-binding compounds, parasites carrying the construct were treated for 6 262 
hours with 0.75M TMPyP4 or TMPyP2 (approximately the 48-hour EC50 dose of 263 
TMPyP4).  Because these compounds do not have any immediate cytocidal effect, 264 
the 6-hour exposure did not cause any visible change in parasite morphology but it 265 
clearly suppressed reporter gene expression relative to the expression of 266 
housekeeping genes.  TMPyP4 – which is the more potent G-quadruplex-binding 267 
analog – had a much stronger effect on transcription than TMPyP2 (Fig. 4D).  The 268 
same assay was then carried out with ~ 48-hour EC50 doses of quarfloxin and NMM, 269 
but owing to the rapid cytocidal effect previously established for these compounds, 270 
only one hour of exposure was used in an attempt to avoid non-specific results 271 
associated with parasite death.  Reporter gene expression was markedly 272 
suppressed by both quarfloxin and NMM (Fig. 4E).   273 
 Having shown that quarfloxin, in common with other G-quadruplex-binding 274 
compounds, can indeed affect the expression of a PQS-encoding gene, we turned to 275 
the expression of rRNA genes, which was previously shown to be suppressed by 276 
quarfloxin in both human cells and trypanosomes (17, 18).  Plasmodium does not 277 
encode its rRNA in conventional tandem arrays and possesses only a few rRNA 278 
genes scattered on various chromosomes (2)(Fig. 5A): these are expressed stage-279 
specifically with A-type genes being used in the blood stages and S-type genes in 280 
mosquito stages (32).  Therefore, RT-PCR was conducted for the A-type genes after 281 
1 hour of quarfloxin exposure, as in Fig. 4E.  In contrast to the effect seen in T. 282 
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brucei, in which rRNA precursor transcripts were dramatically suppressed after just 283 
15 minutes of quarfloxin exposure (17), there was no loss of these transcripts in P. 284 
falciparum; in fact the transcript level rose somewhat (Fig. 5B) and this effect was 285 
broadly mirrored in the level of mature 18S rRNA (Fig. 5C).  Thus, the mode of 286 
action of quarfloxin in P. falciparum is evidently different from that previously 287 
characterised in both T. brucei and human cells.  288 
 As a fluoroquinolone, quarfloxin shares limited structural similarity with the 289 
well-established 4-aminoquinoline drugs (chloroquine, mefloquine, etc.), which kill 290 
Plasmodium parasites by inhibiting haemozoin crystallisation in the food vacuole 291 
(33).  This therefore presented another possible mode of action for quarfloxin, but 292 
the drug’s high potency against pre-replicative ring stages, the fact that its BRRoK 293 
profile is distinct from that of chloroquine, and the fact that the drug does not prevent 294 
haem crystallisation in vitro (Fig. S5) all suggest that quarfloxin does not actually act 295 
in the same mode as 4-aminoquinolines.  The true target of quarfloxin in 296 
Plasmodium parasites remains unknown, but it is apparently neither the haem 297 
detoxification pathway (Fig. S5) nor the production of ribosomal RNA (Fig. 5).   298 
DISCUSSION 299 
This is to our knowledge the first experimental investigation of the biological roles of 300 
G-quadruplex motifs in the malaria parasite P. falciparum.  We demonstrate that G-301 
quadruplex DNA can be detected in this parasite and that disrupting the normal 302 
processing of G-quadruplex motifs impairs parasite growth in vitro.  It is important to 303 
note that sequences with the potential to form G-quadruplexes are very scarce in the 304 
P. falciparum genome and that the G-quadruplexes detected in P. falciparum nuclei 305 
using structure-specific antibodies are likely to be primarily in telomeres, since the 306 
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majority of all PQSs in P. falciparum are tandemly arrayed in telomere repeats (10) 307 
and such antibodies probably cannot detect G-quadruplexes at single-motif 308 
resolution (34).  (Indeed, the G-quadruplex signal seen in late-stage parasites 309 
appears to be strongest in nuclear-peripheral foci, as expected of telomeric DNA.)   310 
However, it is also important to note that the G-quadruplex-forming potential of the P. 311 
falciparum genome may be underestimated by standard in silico algorithms, as was 312 
recently demonstrated by sequencing the human genome with a G-quadruplex-313 
sensitive method (8): this empirical approach detected many more G-quadruplexes 314 
than the in silico method of scanning the genome for repetitions of G3N1-7 (7).  For 315 
the P. falciparum genome, a relatively relaxed predictive algorithm was used in our 316 
previous study (G3N0-11) and this still found just 80 non-telomeric PQSs (5); however, 317 
the algorithm will overlook many of the non-canonical G-quadruplexes detected in 318 
the human genome, such as ‘bulged’ G-quadruplexes (8) and inter-strand rather 319 
than intra-strand G-quadruplexes (9).  Finally, the structure-specific antibody used 320 
here detects only DNA and not RNA G-quadruplexes, so the existence of RNA G-321 
quadruplexes in P. falciparum remains to be confirmed. 322 
 Several G-quadruplex-stabilising compounds were shown to inhibit malaria 323 
parasite growth, including the Phase-2 anticancer drug quarfloxin, which was potent 324 
and relatively fast-acting against both ring and trophozoite parasites.  An ideal 325 
antimalarial should kill parasites at all stages of the intraerythrocytic cycle (and, 326 
indeed, ideally at non-erythrocytic phases of the lifecycle as well).  For example, the 327 
current first-line antimalarial drug, artemisinin, kills prereplicative ring stages as well 328 
as trophozoites and schizonts, whereas older antimalarials such as chloroquine and 329 
antifolates are highly active only against replicative stages.  Whilst it is not essential 330 
to elucidate the molecular mechanism(s) of an antiplasmodial compound prior to 331 
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clinical development – indeed, the mechanism of artemisinin remains poorly 332 
understood – this information can help in predicting the development of drug 333 
resistance and cross-resistance.  Therefore, we investigated the mode of action for 334 
quarfloxin.  We found no evidence that quarfloxin kills parasites by inducing telomere 335 
dysfunction, despite the predominance of PQSs in telomere repeats, since telomere 336 
maintenance appeared to be normal after up to 15 cycles of growth in quarfloxin.  337 
This does not conclusively exclude the possibility of an acutely lethal telomere 338 
dysfunction being induced at higher drug exposures, but the tools to assess this in P. 339 
falciparum are lacking: the parasite lacks the variant histone H2AX (35) which is 340 
commonly used to detect DNA damage foci, and also lacks all components of the 341 
conventional telomere shelterin complex (36).   342 
 In the absence of any clear effect on telomeres, we assessed the possibility 343 
that quarfloxin might kill parasites by preventing the proper expression of G-344 
quadruplex-containing genes.  41 PQSs are predicted in non-var genes (5), many of 345 
which may be essential (by contrast, var gene expression is dispensable in vitro (37), 346 
albeit vital in vivo for virulence phenotypes such as intravascular adhesion, antigenic 347 
variation and immune evasion).  As proof of concept, a G-quadruplex-encoding rifin 348 
reporter gene was cloned, validated and transfected into parasites, and its 349 
expression was shown to be suppressed by all of the G-quadruplex-binding 350 
compounds tested.  This is the first demonstration of G-quadruplex-dependent gene 351 
expression in P. falciparum and it conforms to a model in which sense-strand G-352 
quadruplexes, when stably formed in DNA, can inhibit transcription by RNA 353 
polymerase II.  354 
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 We then assessed the model for quarfloxin action that was previously 355 
reported in trypanosomes and human cells: suppression of rRNA transcription by 356 
RNA polymerase I (17, 18).  We focussed only upon the nuclear rRNA genes, not 357 
those encoded in the apicoplast organelle, because interfering with protein synthesis 358 
in the apicoplast of P. falciparum gives a characteristic ‘delayed death’ phenotype, 359 
with death occurring only in the second growth cycle after drug addition (38), 360 
whereas the parasite death observed here with quarfloxin was very rapid, making 361 
apicoplast ribosomes highly unlikely to be a key target.   362 
 Although P. falciparum expresses its rRNA genes via RNA polymerase I, it 363 
does not maintain these genes in conventional tandem arrays (2) and furthermore, 364 
most of the parasite’s rRNA genes are not predicted to contain PQSs (5).  Only one 365 
atypical locus on chromosome 8, PF3D7_0830000, which contains 5.8S and 28S 366 
rRNA genes but no 18S rRNA, contains a G3N0-11 motif.  It is therefore arguably not 367 
surprising that we did not find any evidence for acute suppression of rRNA 368 
transcription by quarfloxin.  Instead, other essential gene(s) that encode PQSs may 369 
be targeted by quarfloxin, and other G-quadruplex-related modes of action such as 370 
acute induction of DNA damage or telomere dysfunction cannot yet be ruled out.  (It 371 
also remains possible that G-quadruplexes are simply not involved: we are currently 372 
conducting further work to establish quarfloxin’s actual mode of action in P. 373 
falciparum, having established that at least one other predictable possibility – the 374 
inhibition of haemozoin crystallisation – is not consistent with our data.)  More 375 
generally, the very diverse rates of kill for the different compounds tested here 376 
suggest that they may vary not only in their absolute affinity for G-quadruplexes but 377 
also in the subset of G-quadruplexes that each compound targets within the 378 
genome. 379 
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 In conclusion, this work shows that G-quadruplex-binding compounds may 380 
have the potential to be repositioned as antimalarials.  Quarfloxin is potent and fast-381 
acting (at least in vitro), it has well-characterised pharmacodynamics in humans as 382 
established from previous cancer trials, and the selective window is at least 40x on 383 
P. falciparum over human cells (111nM compared to 4.44M on human breast 384 
epithelial cells, as reported by Kerry et al. (17)).  G-quadruplex biology in malaria 385 
parasites thus constitutes an exciting area for future study, both to improve our 386 
understanding of basic biology and virulence gene control in this parasite, and also 387 
to support the discovery of novel targets for antimalarial drug development.  388 
MATERIALS AND METHODS 389 
Parasite culture and drugs 390 
The 3D7 strain of P. falciparum was obtained from the Malaria Research and 391 
Reference Reagent Resource Center (MR4) and the NF54attB strain, from Professor 392 
David Fidock.  The luciferase-expressing Dd2 strain is previously described (39).  393 
Parasites were cultured as previously described (40).  Parasite growth and 394 
morphology was assessed on blood smears stained with Hemacolor (Merck). 395 
Synchronised parasite cultures were obtained by performing two treatments with 5 % 396 
D-sorbitol (41) 42 h apart, to yield an approximately 4-h window of ring stage 397 
parasites.  3D7 parasites were used in all experiments except the gene-expression 398 
studies, which were performed in NF54attB, and the BRRoK assays which were 399 
performed in both NF54 and Dd2 backgrounds.   The compounds NMM, TMPyP4 400 
and TMPyP2 were obtained from Frontier Scientific and quarfloxin from Tetragene 401 
LLC, solubilized in water and stored without exposure to light at -20°C. 402 
Immunofluorescence assay 403 
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For G-quadruplex detection using the IH6 antibody, air-dried blood smears were 404 
fixed with 2% paraformaldehyde/PBS for 2 min and then 90% acetone/10% 405 
methanol for 2 min at 4°C.  Smears were air-dried, blocked with 1% BSA/PBS and 406 
sequentially treated with primary and secondary antibodies.  Antibodies used were 407 
the anti-G-quadruplex monoclonal IH6 (Biorbyt), rabbit polyclonal antibodies to the P. 408 
falciparum cis-Golgi marker ERD2 (obtained from MR4, MRA-1 (42)), Cy3-409 
conjugated anti-rabbit IgG (Jackson ImmunoResearch) and Alexa Fluor 488-410 
conjugated anti-mouse IgG (Thermo Fisher Scientific).  For enzymatic treatments, 411 
slides were incubated after fixation with 0.12 U μL-1 Turbo DNase (Albion) or with 412 
100 μg mL-1 RNase A (Thermo Fischer Scientific) for 1 h at 37 °C.  Slides were 413 
mounted with ProLong Diamond containing DAPI (Thermo Fisher Scientific) and 414 
were imaged with an EVOS cell imaging system (Thermo Fisher Scientific).  415 
Parasites were visualised and images captured using the same exposure for each 416 
fluorochrome across all treatments.   417 
 For G-quadruplex detection using the BG4 antibody, parasites were first 418 
removed from host erythrocytes using 0.4% saponin, then fixed in 4% 419 
paraformaldehyde/PBS.  Fixed parasites were dispensed onto a 12 multi-spot well 420 
slide (Thermo Fisher Scientific) and air-dried. All subsequent steps were carried out 421 
at room temperature in 10L volume.  The parasites were permeabilized with 0.1% 422 
Triton in PBS, washed with PBS, then blocked in 3% bovine serum albumin in PBS 423 
for 1.5 h. Antibody staining steps were: flag-tagged BG4 antibody (EMD Millipore) for 424 
1.5h; rabbit anti-flag antibody (Cell Signalling Technology) for 1.5h; Cy3 conjugated-425 
anti rabbit secondary antibody (Jackson ImmunoResearch) for 1h.  Slides were 426 
washed three times with PBS after each step.  Mounting and visualisation were as 427 
described above. 428 
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Malaria SYBR Green I-based fluorescence (MSF) assay 429 
MSF assays were carried out as previously described (26).  Trophozoite-stage 430 
cultures (75 μL, 1 % parasitaemia, 4 % haematocrit) were added to 96-multiwell 431 
plates containing triplicate wells of 75 μL complete medium pre-dosed with 432 
compounds.  On each assay plate, 3 wells containing 150 μL trophozoite-stage 433 
culture (0.5 % parasitaemia, 2 % haematocrit) in the absence of drugs served as a 434 
positive control (100% growth).  The outer wells of each 96-well plate were filled with 435 
200 μL of medium to prevent evaporation.  Plates were incubated for 48 h in a 436 
gassed (1% O2, 3% CO2, and 96% N2) chamber at 37 °C.  Following this, 100 μL of 437 
the sample from each well was mixed with 100 μL MSF lysis buffer (20 mM Tris pH 438 
7.5, 5 mM EDTA, 0.008% saponin, 0.8% Triton X-100) supplemented with 0.2 μL 439 
mL-1 of SYBR Green I (Sigma).  After a 1-h incubation in the dark at room 440 
temperature, SYBR Green I fluorescence was measured using the blue fluorescent 441 
module (excitation 490 nm: emission 510-570 nm) of a GloMax multidetection 442 
system (Promega).  Percentage parasite growth was calculated as follows: 100x[μ(s) 443 
- μ(-)/μ(+) - μ(-)] where μ(s), μ(-) and μ(+) are the means of the fluorescent readouts from 444 
sample wells, from control wells without drug (100 % growth) and from wells with the 445 
maximum drug concentration (0 % growth), respectively.  EC50 values were 446 
determined by plotting log concentration normalized response curves using 447 
GraphPad Prism v5.0 (GraphPad Software, Inc., San Diego, CA) from the mean of 448 
three independent biological repeats. 449 
Bioluminescence Relative Rate of Kill (BRRoK) assay 450 
BRRoK assays were carried out as described (31).  Trophozoite- cultures of Dd2luc 451 
or NF54 luc (100μl, 2% parasitaemia, 4% haematocrit) were added to 96-multiwell 452 
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plates containing 100μl of pre-dosed complete culture medium (three-fold EC50 453 
dilution series, 9xEC50 to 0.33xEC50 for each compound tested), mixed by pipetting 454 
and incubated for 6 h at 37°C.  Samples of 40 μL were removed from each well and 455 
the bioluminescence signal was measured using the luciferase single-step lysis 456 
protocol (43). Controls in each biological replicate consisted of trophozoite stage 457 
culture with no drug added (100% bioluminescence). The normalised 458 
bioluminescence data from three biological repeats was plotted as a proportion of 459 
the untreated control, with reference data for benchmark antimalarial compounds 460 
sourced from (31).  461 
Flow Cytometry 462 
Parasite cultures were washed in PBS and then stained for flow cytometry using 463 
SYBR Green 1 diluted 1:2000 in PBS, incubated at room temperature without light 464 
exposure for 20 minutes.  Parasites were then fixed in 4% formalin (Sigma) in PBS, 465 
incubated at 4°C for 15 minutes, before thorough washing in PBS and analysis using 466 
forward scatter and the green fluorescence channel of a Guava easyCyte System 467 
(Merck Millipore). 468 
Southern blotting 469 
Genomic DNA was extracted from parasites using the QIAamp DNA Blood Mini Kit 470 
(Qiagen) and digested with restriction enzymes AluI, DdeI, MboII and RsaI as 471 
previously described (44).  Digested genomic DNA was resolved on a 1 % agarose 472 
gel, transferred to GenScreen Plus (PerkinElmer) and hybridised with a probe 473 
specific for telomeres (45), labelled with alkaline phosphatase (AlkPhos Direct 474 
Labelling and Detection system, GE Healthcare) and then imaged according to the 475 
kit manufacturer’s directions.   476 
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Plasmid construction and parasite transfection to generate Rifin-GFP reporter 477 
line  478 
To generate the G-quadruplex reporter line the rifin gene PF3D7_0700200 was 479 
amplified using the primers TGCCTAGGATGAAAATCCATTATATTAAT and 480 
ACCGTACGTTCTTTTAATAGTTTTATGTATG, then cloned upstream of the C-481 
terminal GFP tag in the pLN-ENR-GFP plasmid (46) to generate the plasmid pLN-482 
Rif0700200-GFP.  NF54attB parasites were transfected with pLN-Rif0700200-GFP 483 
and maintained on BSD selection as previously described (46, 47).   484 
Biophysical characterization of G-quadruplex formation 485 
Oligonucleotide TTTGGGAGGGCTTGTTCCGGGAATGGGTT was purchased from 486 
Eurofins Genomics (Ebersberg, Germany) and was resuspended in MilliQ water to 487 
generate a stock solution at 400 µM. Before experiments, the oligonucleotide was 488 
annealed by heating at 90 °C for 3 minutes. Cation solution (KCl or LiCl) and lithium 489 
cacodylate were then added to reach final concentrations of 150 and 10 mM 490 
respectively, and a pH of 7.4.  For thermal denaturation, oligonucleotide final 491 
concentration was 2.5 µM and UV absorption was recorded at 295 nm on a Uvikon 492 
XS spectrophotometer (Seconam), using 1 cm path-length quartz cell (Hellma, type 493 
No. 115B-QS, France). NMR samples were prepared by dissolving the 494 
oligonucleotides in H2O/D2O 95/5, lithium cacodylate 10 mM, pH 7.4 for a final 495 
oligonucleotide concentration of 200 μM. NMR data were collected at 500 MHz on a 496 
Bruker Avance spectrometer (fitted with a TCI triple resonance cryo-probe with z-497 
axis gradient). 1D 1H spectra were recorded at a temperature of 25°C. Water 498 
suppression was achieved using excitation sculpting with gradients (48).  499 
Gene expression analysis 500 
 22 
Total RNA was extracted from mixed-stage cultures of parasites transfected with 501 
pLN-Rif0700200-GFP using the RNeasy kit (Qiagen).  Extracted RNA was treated 502 
with DNaseI and cDNA was subsequently synthesised using the iScript cDNA 503 
Synthesis Kit (BIO-RAD).  cDNA was checked for genomic DNA contamination by 504 
PCR across the intron of the gene PF3D7_0424300, as previously described (49).  505 
Relative gene expression was determined by real-time PCR using a StepOnePlus 506 
Real-Time PCR machine (ThermoFisher Scientific) and the SensiFAST SYBR Hi-507 
ROX kit (Bioline) on synthesised cDNAs.  Cycling conditions were 95°C for 3 508 
minutes, 40 cycles of 95°C for 15 seconds, 45°C for 40 seconds, 60°C for 1 minute.  509 
The three housekeeping genes used as controls were PF3D7_0717700 (seryl-tRNA 510 
synthetase), PF3D7_1444800 (fructose bisphosphate aldolase) and 511 
PF3D7_1246200 (actin): primers for these genes are previously described (50).  A1 512 
and A2 rRNA transcripts, and mature 18S rRNA, were also measured using primers 513 
previously described (51).  The GFP-tagged reporter gene was measured using the 514 
GFP-specific primers GATGGAAGCGTTCAACTAGCAGACC and 515 
AGCTGTTACAAACTCAAGAAGGACC.  Ct analysis (Ct, threshold cycle) was 516 
used to calculate the relative copy number of each target gene relative to the 517 
average Ct of the three control genes.  All experiments were conducted in both 518 
biological and technical duplicate. 519 
Haem crystallisation assay 520 
This assay was carried out as previously described (52), with the slight modification 521 
of using NP-40 rather than Tween-20 to initiate crystallisation (as per (53)).  500M 522 
quarfloxin was added because previous work showed that the equivalent level of 523 
chloroquine could produce the maximal (75%) inhibition of crystallisation (52).  The 524 
conventional readout of this assay, haem absorbance at 415nm, was precluded by 525 
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interference from the strong intrinsic colour of quarfloxin, and the assay could 526 
therefore be assessed only by non-quantitative visual observation of the crystals 527 
formed.   528 
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FIGURE LEGENDS 702 
Figure 1: G-quadruplexes can be detected in P. falciparum parasites  703 
(A) Schematic of a G-quadruplex DNA motif.  Guanine tetrads are shown as green 704 
squares and guanine backbones as dashed black lines.  G-quartets stack on top of 705 
one another to form the quadruplex, which is stabilized by cations such as potassium 706 
(K+).  An example of a PQS that could fold into such a structure is shown below. 707 
 (B) Immunofluorescence images showing G-quadruplexes detected with the 708 
structure-specific antibody IH6 in P. falciparum intraerythrocytic stages (3D7 parasite 709 
strain).  Images are representative of 3 independent experiments, examining mixed-710 
stage cultures.     711 
(C) DNase treatment abolishes G-quadruplex (IH6) staining but has no effect on the 712 
distribution of a protein, ERD2, used as a control (middle row).  RNase treatment has 713 
no discernible effect on G-quadruplex (IH6) staining (bottom row).  Images are 714 
representative of 3 independent experiments.   715 
 716 
Figure 2: G-quadruplex-binding drugs inhibit parasite growth 717 
(A) The G-quadruplex-binding drugs NMM, Quarfloxin, TMPyP2 and TmPyP4 inhibit 718 
the in vitro growth of P. falciparum (3D7 parasite strain) to varying extents.  719 
Percentage parasite growth is plotted as a function of [compound], error bars are 720 
standard error of the mean.  The mean EC50 values from 3 independent Malaria 721 
SYBR Green I-based fluorescence (MSF) assays are tabulated and 95% confidence 722 
intervals are shown.   723 
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(B,C) EC50 concentration-dependent loss of normalised bioluminescence signal in 724 
BRRoK assays against (C) benchmark antimalarials and (D) G-quadruplex-725 
stabilising compounds.  The mean bioluminescence signal (normalised against an 726 
untreated control) remaining in Dd2luc P. falciparum after a 6 h exposure to the 727 
indicated fold-EC50 concentration of each drug or compound is plotted.  Error bars 728 
represent ±SD from three biological replicates.  ATQ, atovaquone; CQ, chloroquine; 729 
DHA, dihydroartemisinin; MQ, mefloquine; NMM, N-methyl-mesoporphyrin IX; QF, 730 
quarfloxin; TmPyP2, 5,10,15,20-tetra-(N-methyl-2-pyridyl) porphine; TmPyP4, 731 
5,10,15,20-tetra-(N-methyl-4-pyridyl) porphine. 732 
 733 
Figure 3: Quarfloxin kills ring-stage parasites as well as replicative stages 734 
Developmental stages of 3D7 parasites were assessed visually at 8 h intervals over 735 
a single growth cycle, starting at the mid-ring stage, either in the absence of drug or 736 
with quarfloxin added at 210nM (approximately 2x EC50) at ring, trophozoite or 737 
schizont stages.  Parasites were also analysed at 8 h intervals for DNA content by 738 
flow cytometry under each of these conditions.  For morphology assessment, 50 739 
parasites were counted at each timepoint and photographs show representative 740 
parasite morphology for each stage; dead parasites stained as a dense intracellular 741 
dot without clear morphological features.  For flow cytometry, 200,000 parasites 742 
were counted in each sample. 743 
 744 
Figure 4: G-quadruplex-binding drugs affect the expression of a G-quadruplex 745 
reporter gene  746 
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(A) Oligonucleotide sequence from gene PF3D7_0700200, used in biophysical 747 
assays to confirm the folding of a G-quadruplex structure. 748 
(B) 1H NMR spectra, acquired at 37°C in 150 mM Li+ (top) and 150 mM K+ (bottom). 749 
Imino protons peaks are only present in K+, in agreement with the inability of Li+ to 750 
stabilize G-quadruplex structures. The relatively low intensity of imino peaks in the 751 
K+ condition seems to indicate the presence of a floppy structure, potentially the 752 
consequence of the second long loop. 753 
(C) Stability of the G-quadruplex as evaluated by thermal denaturation, followed at 754 
295 nm. 755 
(D) Expression of the GFP-tagged G-quadruplex reporter gene PF3D7_0700200 in 756 
transgenic parasite cultures treated with 0.75M TMPyP4 or TMPyP2 for 6 h.  757 
Expression was determined by quantitative real-time PCR using primer pair 758 
GFP_F/R as compared to average expression of three housekeeping genes 759 
encoding actin, seryl tRNA synthetase and fructose bisphosphate aldolase.  The 760 
experiment was carried out in both biological and technical duplicate, error bars are 761 
standard error of the mean and statistical significance was assessed by 1-tailed t-762 
test (**, p<0.01; ***, p<0.001).   763 
(E) Expression of the GFP-tagged G-quadruplex reporter gene PF3D7_0700200 in 764 
transgenic parasite cultures treated with 120nM quarfloxin or 80M NMM for 1 h, 765 
determined as in (D). 766 
 767 
Figure 5: Quarfloxin does not inhibit the expression of rRNA genes  768 
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(A) Schematic showing the locations of rRNA-encoding units on the 14 769 
chromosomes of the P. falciparum genome, together with their type (A, blood-stage 770 
expressed; S, mosquito-stage expressed).  The locations of primers used to 771 
measure rRNA transcription are also shown. 772 
(B) Expression of rRNA A1/2 transcripts in the same parasites as used in Figure 4E, 773 
after treatment with 120nM quarfloxin for 1 h.  Target gene expression was 774 
determined relative to three control genes, as in Figure 4: error bars are standard 775 
error of the mean and statistical significance was assessed by 1-tailed t-test (**, 776 
p<0.01).   777 
(C) Expression of mature 18S rRNA in the same parasites as used in Figure 4E, 778 
after treatment with 120nM quarfloxin for 1 h.   779 
 780 





